The Mako SmartRobotics system from Stryker Corp. - precision knee and hip surgeries across US hospitals

The Mako SmartRobotics system from Stryker enables orthopedic surgeons to plan and execute knee and hip procedures with CT-based 3D models and robotic-arm assistance in hundreds of US hospitals. Anyone holding Stryker Corp. stock (NYSE: SYK, ISIN US8636671013) should know this product.

By Thomas Riley, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 5:30 AM ET. Details in the imprint.

Walking into an orthopedic OR where a Mako SmartRobotics system hums quietly in the corner, you notice the slim robotic arm parked beside a draped knee and a high-resolution display showing a patient-specific 3D bone model in sharp blues and grays. A scrubbed surgeon in lead glasses nudges the robotic arm into position with a gloved hand while a circulating nurse taps through the preoperative plan on the touchscreen. The Mako SmartRobotics system from Stryker Corp. has become a familiar sight in many US joint-replacement suites, blending traditional surgical skill with data-heavy guidance and controlled bone preparation.

How Mako SmartRobotics works in the OR

The core of the Mako platform is CT-based planning and robotic-arm assisted bone preparation for procedures such as total knee, partial knee, and total hip arthroplasty, all tied to FDA-cleared workflows that integrate with Stryker’s implant portfolio. The process typically starts days before surgery when a CT scan is used to generate a 3D model of the patient’s joint, allowing the surgeon to define implant size, alignment, and resection boundaries with millimeter-level targets on dedicated planning software. During the actual operation, optical trackers and arrays mounted to the bone help the system register the patient’s anatomy to the preoperative model, so when the surgeon moves the Mako arm to resect bone, the software constrains the bur or saw within the planned resection volume through a so?called haptic boundary.

Surgeons like Dr. Michael Mont, an orthopedic specialist quoted in Stryker’s educational materials, emphasize that they remain in full control of the arm; the system does not move autonomously but instead provides real-time feedback, vibration cues, and automatic stop at the edge of predefined safe zones. On the Mako console, color-coded maps show current resection depth and alignment, and as bone is cut, the software updates predicted implant positioning and soft-tissue balancing characteristics, which can help the surgeon adjust component rotation or varus-valgus alignment on the fly. In practice, that means what used to be a largely manual alignment process guided by jigs and long intramedullary rods can be replaced by a guided workflow where each step is digitally cross-checked.

Clinical focus on consistency and alignment

A significant part of the case for robotic-arm assistance in joint replacement revolves around consistency: the idea that accurate alignment and controlled bone removal across many surgeons and hospitals can support better function and potentially lower revision rates over time. Published studies summarized in Stryker’s Mako clinical evidence compendium report that Mako total knee procedures can yield lower rates of outliers in coronal alignment compared with conventional jig-based techniques, and some series have shown improved early functional scores and patient-reported satisfaction, although long-term data are still being gathered. In unicompartmental knee arthroplasty, where component placement is especially sensitive to minor deviations in slope or rotation, several peer-reviewed papers cited by Stryker suggest that robotic assistance can tighten the spread of alignment results, which is critical because malpositioned partial knees historically have carried higher revision risks.

In total hip arthroplasty, the Mako workflow allows surgeons to plan cup inclination and anteversion as well as leg length and offset based on CT data, then place the acetabular component within a pre-defined safe zone that accounts for the patient’s specific spinopelvic mobility. On the table, that can translate into fewer dramatic leg length discrepancies and potentially reduced dislocation risk, especially in patients with spinal fusion or abnormal pelvic tilt, although, again, orthopedic societies emphasize that robust long-term comparative data are still evolving. For US hospitals that market their orthopedic centers to an aging population accustomed to technology in other parts of life, the visible presence of a robotic arm and a large planning display has also become a differentiator in local competition, even though clinical value must remain rooted in data rather than the optics of the device.

US market footprint and hospital economics

The Mako SmartRobotics platform entered the US market initially through partial knee and hip indications and has since expanded to total knee, with Stryker reporting thousands of systems installed globally and a strong concentration in North America according to its annual filings. A complete Mako setup, including the robotic arm, planning workstation, and associated tools, represents a multi-million-dollar capital investment for a hospital, which means capital budgeting committees scrutinize not just clinical data but also volume projections and competitive positioning. To support adoption, Stryker typically offers a combination of purchase and service arrangements plus recurring revenue on procedure-specific disposables such as cutting accessories and arrays, so a busy joint-replacement center performing hundreds of Mako cases per year becomes an annuity-like revenue source for the company.

US hospital CFOs weigh those recurring costs against potential efficiency gains: standardized workflows can shorten the learning curve for newer surgeons, and in some institutions, predictable component placement and alignment data are being linked to bundled-payment models that reward lower complication and revision rates over multi-year horizons. Orthopedic department chiefs like Dr. Andrew Pearle at Hospital for Special Surgery, who has published on robotic joint replacement (though not exclusively tied to any one platform), describe how scheduling high-volume robotic days and tightly coordinated room turnover can keep utilization rates high enough to justify the capital cost. For community hospitals, the calculus often includes marketing; being able to put "robotic joint replacement" on billboards and local TV spots can draw patients who might otherwise drive to a regional academic center.

Surgeon training and workflow changes

From the surgeon’s perspective, adopting Mako SmartRobotics involves a shift in preoperative planning habits and intraoperative technique rather than a complete reinvention of joint replacement fundamentals. Stryker runs dedicated training courses and cadaver labs where orthopedic surgeons spend a day or two working through simulated cases, guided by proctors who have used the system extensively in their own practice, before moving on to proctored live cases in their home hospitals. According to senior Stryker leader Robert Cohen, referenced in company presentations on enabling technologies, early adopters often become internal champions who help train colleagues and refine OR logistics such as how to position the robot in crowded rooms and when to run system checks so they do not delay incision time.

Once training ramps are complete, surgeons often report that the most visible change in the room is the amount of on-screen data available at each step: gap-balancing curves, live updates as bone is removed, and a clear depiction of implant placement relative to mechanical and anatomical axes. For some seasoned surgeons, this additional information reinforces decisions they were already making intuitively; for younger surgeons, it can provide a confidence boost as they build case volumes. Professional societies emphasize that robotic platforms like Mako should complement, not replace, fundamental knowledge of biomechanics and manual skills, because unexpected intraoperative findings still require judgment that no software can fully script.

Regulatory status and competing systems

In the US, the Mako SmartRobotics system and associated joint replacement applications have clearances through the Food and Drug Administration as Class II medical devices, following the 510(k) pathway leveraging predicate devices and clinical data. That regulatory status aligns Mako with other orthopedic robotic systems rather than treating it as an experimental technology, although hospitals still typically review internal outcomes and safety metrics after adoption. Stryker’s system competes with robotic and computer-assisted platforms from companies such as Zimmer Biomet, Smith & Nephew, and DePuy Synthes, each with its own approach to imaging, registration, and implant ecosystem linkage.

This competition has nudged all players to emphasize ease of setup, reduced registration time, and integration into existing instrument trays, because OR staff do not have endless capacity to manage additional equipment. In some markets, purchasing committees look at multi-vendor lineups and choose a single robotics platform as their standard, which can influence implant share for years, since most systems are tightly bound to their own manufacturer’s hardware. For Stryker, Mako’s advantage lies in its association with widely used Triathlon knee and Accolade hip implants and a long operational runway as surgeons continue migrating toward technology-assisted procedures.

What it means for Stryker Corp. and investors

Stryker Corp. positions Mako SmartRobotics as a central pillar of its orthopedic growth strategy, pairing the installed base with implants, instruments, disposables, and service contracts that collectively build a sizable revenue stream within the MedSurg and Neurotechnology and Orthopaedics and Spine reporting segments. For US retail investors looking at the broader orthopedic device landscape, Stryker stock (NYSE: SYK) is often analyzed with a particular focus on how fast hospitals are adopting enabling technologies like Mako and how consistently those systems are used in day-to-day practice.

Key facts on Mako SmartRobotics

• Product: Mako SmartRobotics system
• Manufacturer: Stryker Corp.
• Category: Classics & longsellers (orthopedic surgical robotics)
• Launch: Initial robotic-arm system introduced in the 2000s with subsequent expansions to total knee and hip indications over the 2010s
• MSRP / Price: Multi-million-dollar capital system per hospital installation (exact pricing varies by configuration and contract)
• Availability: Installed in thousands of hospitals worldwide with strong penetration in US joint-replacement centers
• Target audience: Orthopedic surgeons and hospitals performing high volumes of knee and hip replacements
• Standout / USP: CT-based preoperative 3D planning combined with robotic-arm assisted bone preparation and haptic boundaries for knee and hip arthroplasty

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.